Share this page
Print this page
Email alert
OVERVIEW
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small molecule therapeutic candidates target specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit off-target effects.
- Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and the initiation of registration trials is planned for 2H 2010.
- CAL-263, an investigational compound targeting PI3K Delta a novel approach for the treatment of inflammatory diseases such as asthma, COPD and autoimmune diseases such as rheumatoid arthritis. Phase 2 trials will begin later in 2010.
- Calistoga Pharmaceuticals continues to evaluate the role of selected isoforms for the treatment of patients with solid tumors in preclinical studies.
Calistoga Pharmaceuticals is a private, venture backed company with top tier investors including Alta Partners, Amgen Ventures, Frazier Healthcare, and Three Arch Partners. The company is led by a seasoned management team, all with experience developing successful commercialized products.